Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, has launched Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). Glenmark’s Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz, Inc. According to IQVIA sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004% market achieved annual sales of approximately $66.2 million.
Glenmark’s current portfolio consists of 200 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1796.65 |
Dr. Reddys Lab | 1219.60 |
Cipla | 1505.00 |
Lupin | 2093.35 |
Zydus Lifesciences | 970.85 |
View more.. |